江中藥業(600750.SH)半年度淨利潤升10.35%至2.52億元
格隆匯8月22日丨江中藥業(600750.SH)發佈2019年半年度報告，實現營業收入11.41億元，同比增長27.44%；歸屬於上市公司股東的淨利潤2.52億元，同比增長10.35%；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.35億元，同比增長4.73%；基本每股收益0.48元。
非處方藥類：品牌渠道聯合發力，謀求業務增長新路徑。聚焦胃腸領域，以健胃消食片和乳酸菌素片為核心，明確產品定位，優化產品訴求，與消費者建立強烈的品牌關聯。健胃消食片強化“肚子脹、不消化”的產品定位，提升消費者黏性；乳酸菌素片啟用“利活”新品牌，聚焦腸道日常調理市場；強化與連鎖的深度合作，不斷創新營銷模式，打造品牌、渠道、公關合力的線上線下推廣模式。完成電商銷售渠道佈局，對原有銷售體系形成互補；開展跨界合作，尋找與年輕人羣尤其是“吃貨人羣”的溝通方式，推動品牌年輕化。此外，積極推動2019年新收購併入的桑海製藥和濟生製藥產品規劃，組建控銷業務線，啟用江中品牌逐步盤活桑海製藥和濟生製藥存量批文及產品。報告期內，本版塊業務報告期內實現營業收入9.04億元，同比增長17.43%。
處方藥類：存量探索新功效，外延融合新發展。本版塊主要為桑海製藥和濟生製藥的處方藥及江中原有的江中牌蚓激酶腸溶膠囊，桑海製藥和濟生製藥的處方藥覆蓋婦科、腸道、呼吸等領域。江中牌蚓激酶腸溶膠囊正式開展臨牀再評價研究，進行新功效探索。因新增併入桑海製藥和濟生製藥業務，報告期內本版塊經營規模大幅增長，實現營業收入1.80億元，同比增長573.82%。
保健品及其他：重新梳理產品定位，探索老品新模式。報告期內，啟動對初元和參靈草系列產品定位的梳理，初步完成初元針對藥店、商超、線上渠道的產品開發規劃和參靈草牌原草液新品規上市流程。由於禮品市場和高端保健品市場整體下滑、消費者購買渠道轉移及部分產品調整，本版塊上半年營業收入同比下降43.33%。
作為融入華潤和融合桑海製藥和濟生製藥的元年，報告期內公司一方面積極融入華潤體系管理，以6S管理體系、5C資金管理體系、EHSQ體系、卓越運營體系等體系對接為抓手，推進組織優化，梳理髮展戰略，為後續高質量發展謀篇佈局。另一方面，有序推進桑海製藥和濟生制藥的融合，進行了財務管理、質量控制、採購監控、產品協同等方面梳理和優化，為規範發展和增強協同奠定基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
